Clinical Trial

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Protocol Amendment History 1 change
notable Trial sites expanded: 30 -> 34 locations 2026-06-24
Trial Details
NCT Number NCT06963021
Lead Sponsor Neurocrine Biosciences
Conditions Major Depressive Disorder
Enrollment 200 participants
Start Date 2025-05-30
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-10